BiotechTube

Rosuvastatin (Crestor)

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hyperlipidemia

Conditions

Hyperlipidemia, Atherosclerosis

Trial Timeline

Mar 1, 2009 → Mar 1, 2012

NCT ID
NCT00885872

About Rosuvastatin (Crestor)

Rosuvastatin (Crestor) is a approved stage product being developed by AstraZeneca for Hyperlipidemia. The current trial status is unknown. This product is registered under clinical trial identifier NCT00885872. Target conditions include Hyperlipidemia, Atherosclerosis.

What happened to similar drugs?

5 of 20 similar drugs in Hyperlipidemia were approved

Approved (5) Terminated (1) Active (14)
🔄YHP1701 + YHR1703 + YHR1704YuhanPhase 3
🔄YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placeboYuhanPhase 3
✅Diet+pravastatinDaiichi SankyoApproved
✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved
✅Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved
🔄Pravafen + Pravastatin + FenofibrateShionogiPhase 3
❌Evacetrapib + Atorvastatin + Ezetimibe + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00885872ApprovedUNKNOWN

Competing Products

20 competing products in Hyperlipidemia

See all competitors
ProductCompanyStageHype Score
DRL-17822 or placeboDr. Reddy's LaboratoriesPhase 2
32
VK2809 + PlaceboViking TherapeuticsPhase 2
32
YHP1701 + YHR1703 + YHR1704YuhanPhase 3
40
YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placeboYuhanPhase 3
40
Diet+pravastatinDaiichi SankyoApproved
43
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved
43
Pravafen + Pravastatin + FenofibrateShionogiPhase 3
40
Evacetrapib + Atorvastatin + Ezetimibe + PlaceboEli LillyPhase 3
32
exenatideEli LillyPre-clinical
26
LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SCEli LillyPhase 1
29
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injectionsJiangsu Hengrui MedicinePhase 1
33
SHR-1209Jiangsu Hengrui MedicinePhase 1
29
SHR-1209 + PlaceboJiangsu Hengrui MedicinePhase 1/2
32
Rosuvastatin + AtorvastatinAstraZenecaPhase 2
35
simvastatin + EzetimibeMerckApproved
43
MK-0524A + Atorvastatin + SimvastatinMerckPhase 3
40
simvastatin 20 mg/ezetimibeMerckPhase 2/3
38
Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for RosuvastatinMerckPhase 3
47
Sitagliptin + PlaceboMerckPhase 2/3
38